

Clinical Colorectal Cancer

Abby Siegel MD, MS

COLON CANCER


1. Epidemiology
2. Risk factors
3. Manifestations
4. Treatment

1. EPIDEMIOLOGY

- Colorectal cancer is the third most common cancer in the United States
- About 150,000 new cases/year
- Most cases in people over 50


Colorectal Cancer Incidence, 2008

Estimated New Cases*


| | | | Males | Females | | | |
|-----------------------|----------------|-------------|---|-----------------------|-------------|-----|--|
| Prostate | 186,320 | 25% |  | Breast | 182,460 | 26% | |
| Lung & bronchus | 114,690 | 15% | | Lung & bronchus | 100,330 | 14% | |
| Colon & rectum | 77,250 | 10% | | Colon & rectum | 71,560 | 10% | |
| Urinary bladder | 51,230 | 7% | | Uterine corpus | 40,100 | 6% | |
| Non-Hodgkin lymphoma | 35,450 | 5% | | Non-Hodgkin lymphoma | 30,670 | 4% | |
| Melanoma of the skin | 34,950 | 5% | | Thyroid | 28,410 | 4% | |
| Kidney & renal pelvis | 33,130 | 4% | | Melanoma of the skin | 27,530 | 4% | |
| Oral cavity & pharynx | 25,310 | 3% | | Ovary | 21,650 | 3% | |
| Leukemia | 25,180 | 3% | | Kidney & renal pelvis | 21,260 | 3% | |
| Pancreas | 18,770 | 3% | | Leukemia | 19,090 | 3% | |
| All Sites | 745,180 | 100% | All Sites | 692,000 | 100% | | |

Colorectal Cancer Deaths, 2009


Estimated New Cases*

| | | Males | | Females | | |
|-----------------------|----------------|-------------|--|-----------------------|----------------|-------------|
| Prostate | 186,320 | 25% |  | Breast | 182,460 | 26% |
| Lung & bronchus | 114,690 | 15% | | Lung & bronchus | 100,330 | 14% |
| Colon & rectum | 77,250 | 10% | | Colon & rectum | 71,560 | 10% |
| Urinary bladder | 51,230 | 7% | | Uterine corpus | 40,100 | 6% |
| Non-Hodgkin lymphoma | 35,450 | 5% | | Non-Hodgkin lymphoma | 30,670 | 4% |
| Melanoma of the skin | 34,950 | 5% | | Thyroid | 28,410 | 4% |
| Kidney & renal pelvis | 33,130 | 4% | | Melanoma of the skin | 27,530 | 4% |
| Oral cavity & pharynx | 25,310 | 3% | | Ovary | 21,650 | 3% |
| Leukemia | 25,180 | 3% | | Kidney & renal pelvis | 21,260 | 3% |
| Pancreas | 18,770 | 3% | | Leukemia | 19,090 | 3% |
| All Sites | 745,180 | 100% | | All Sites | 692,000 | 100% |

Estimated Deaths

| | | Males | | Females | | |
|--------------------------------|----------------|-------------|--|--------------------------------|----------------|-------------|
| Lung & bronchus | 90,810 | 31% |  | Lung & bronchus | 71,030 | 26% |
| Prostate | 28,660 | 10% | | Breast | 40,480 | 15% |
| Colon & rectum | 24,260 | 8% | | Colon & rectum | 25,700 | 9% |
| Pancreas | 17,500 | 6% | | Pancreas | 16,790 | 6% |
| Liver & intrahepatic bile duct | 12,570 | 4% | | Ovary | 15,520 | 6% |
| Leukemia | 12,460 | 4% | | Non-Hodgkin lymphoma | 9,370 | 3% |
| Esophagus | 11,250 | 4% | | Leukemia | 9,250 | 3% |
| Urinary bladder | 9,950 | 3% | | Uterine corpus | 7,470 | 3% |
| Non-Hodgkin lymphoma | 9,790 | 3% | | Liver & intrahepatic bile duct | 5,840 | 2% |
| Kidney & renal pelvis | 8,100 | 3% | | Brain & other nervous system | 5,650 | 2% |
| All Sites | 294,120 | 100% | | All Sites | 271,530 | 100% |

Age-Adjusted Cancer Death Rates, * Males by Site, US, 1930-2002




*Per 100,000, age-adjusted to the 2000 US standard population.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancer of the liver, lung and bronchus, and colon and rectum are affected by these coding changes.

Source: US Mortality Public Use Data Tapes 1960 to 2002, US Mortality Volumes 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2005.

American Cancer Society, Surveillance Research, 2006

Age-Adjusted Cancer Death Rates,* Females by Site, US, 1930-2002



*Per 100,000, age-adjusted to the 2000 US standard population. †Uterus cancer death rates are for uterine cervix and uterine corpus combined.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancer of the lung and bronchus, colon and rectum, and ovary are affected by these coding changes.

Source: US Mortality Public Use Data Tapes 1960 to 2002, US Mortality Volumes 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2005.

American Cancer Society, Surveillance Research, 2006

EPIDEMIIOLOGY

- Incidence rates high in U.S.,
Europe, Australia
- Increasing in Japan
- Low in China, Africa

EPIDEMIOLOGY

- Changes in incidence rates over time and with migration may indicate role of environmental factors

2. RISK FACTORS: Protective

- Exercise
- NSAIDS
- ? Calcium/Vitamin D
- ? Fiber
- ? Folic Acid

NSAIDS

1) Cox-1 and Cox-2 inhibition

- Aspirin, Ibuprofen

- Bleeding risk

2) Selective Cox-2 inhibition

- Rofecoxib (Vioxx),

- Celecoxib (Celebrex)

- Thrombosis risk

RISK FACTORS: Increased risk with...

- Advanced age
- Inflammatory bowel disease
- Consumption of high-fat diet
- Personal or family history of colon cancer


FAMILIAL SYNDROMES

- HNPCC
 - Hereditary non-polyposis colon cancer
- APC
 - Adenomatous polyposis coli
- Both usually autosomal dominant

HNPPC (Lynch Syndrome)

Hereditary Non-Polyposis Colon Cancer

- 2-5% of colon cancers
- Caused by mutations in mismatch repair genes
- Tend to present in the right colon
- Often associated with endometrial cancer in women
- Start screening early 20s



HNPPC Increases the Risk of Colorectal Cancer

By age 50

By age 70



Population Risk

HNPPC Risk

0.2%

>25%

2%

80%

Gastroenterology 1996;110:1020-7

Int J Cancer 1999;81:214-8

HNPPC Increases the Risk of Endometrial Cancer

By age 50

By age 70



Population Risk

0.2%

1.5%

HNPPC Risk


20%

60%

Gastroenterology 1996;110:1020-7

Int J Cancer 1999;81:214-8


HNPCC: Cancer Risks





APC

Adenomatous Polyposis Coli

- Less than 1% of colon cancers
- Caused by mutation of APC gene (5q21)
- Also associated with duodenal cancers, desmoid tumors, “CHRPE” (congenital hypertrophy of the retinal pigment epithelium)
- Start screening at puberty








3. MANIFESTATIONS

1. Growth of cancer at primary site
2. Metastatic spread



MANIFESTATIONS

1. Growth of cancer at primary site
 - a. Asymptomatic/screening
 - b. Right sided syndrome
 - c. Left sided syndrome


MANIFESTATIONS

1. Growth of cancer at primary site

i. Asymptomatic

- Detected by screening test
 - Fecal occult blood
 - Sigmoidoscopy
 - Colonoscopy
 - “Virtual” colonoscopy
 - Molecular techniques

Virtual Colonoscopy




Pickhardt et al. NEJM, 349 (23): 2191, 2003

Screening summary

- Average risk: colonoscopy every 10 years over age 50
- Family history: colonoscopy 10 years before index case
- Dysplastic polyps: repeat colonoscopy after 3 years

Screening, continued...

- APC: annual flexible sigmoidoscopy starting at age 11, colectomy when polyps develop
- HNPCC: colonoscopy at age 21, then every 1-2 years
- Inflammatory bowel disease: start 8 years after pancolitis, 12 years after distal disease



MANIFESTATIONS

1. Growth of cancer at primary site
 - ii. Right sided syndrome
 - a) Ascending colon has thin wall, large diameter, distensible
 - b) Liquid fecal stream
 - c) Chronic blood loss results in iron deficiency anemia***
 - d) Obstruction unlikely


MANIFESTATIONS

1. Growth of cancer at primary site

iii. Left sided syndrome

- a) Descending colon wall thicker, less distensible
- b) More solid fecal stream
- c) Tumors tend to infiltrate
- d) Bright red blood more common
- e) Obstruction more common


“Apple core lesion”



COMPARISON RIGHT AND LEFT SIDED COLON CANCERS


| | Right | Left |
|------------------------|-------|------|
| Anemia | +++ | + |
| Occult bleeding | +++ | + |
| Gross bleeding | + | +++ |
| Abd. Mass | ++ | + |
| Change in bowel habits | + | +++ |
| Obstruction | + | +++ |

Stage 1 Colorectal Cancer




- 23% of colorectal CA
- Cancer has grown through the mucosa and invades the muscularis
- Treatment: surgery to remove the tumor and some surrounding lymph nodes
- Survival: 93%

Stage 2 Colorectal Cancer




- 31% of colorectal CA
- Cancer grows beyond the muscularis of the colon or rectum but has not spread to the lymph nodes
- Treatment (colon): surgery +/- adjuvant chemotherapy
- Survival: 72 to 85%
- Treatment (rectal): surgery, radiation and chemo

Stage 3 Colorectal Cancer



- 26% of colorectal CA
- Cancer has spread to the regional lymph nodes
- Treatment (colon): surgery and adjuvant chemotherapy
- Survival: 44 to 83%
- Treatment (rectal): surgery, radiation and chemotherapy

Stage 4 Colorectal Cancer



- 20% of colorectal CA
- Cancer has spread to other areas of the body
- Treatment: chemotherapy. Consider surgery of primary lesion, especially if symptomatic
- Surgery to remove metastases (liver/lung) in carefully selected patients
- Survival: 8%

PROGNOSIS depends on...

1. Histological features

- poor differentiation
- vascular invasion

2. Depth of invasion

3. Nodal involvement

4. Genetic alterations

- 18q LOH (bad), MSI (good), K-ras mutation
(limits response to anti-EGFR antibodies)

MANIFESTATIONS

Metastatic Spread


1. Lymphatics

Mesenteric nodes

Virchow's node

2. Hematogenous spread

Liver via portal circulation



Metastases



LIVER METASTASES

MANIFESTATIONS

1. Pain (stretching capsule)
2. Hepatomegaly, nodularity
3. Elevated liver function tests

4. TREATMENTS

1. Surgery

- Localized disease (Stage I, II, III)
- Try to remove isolated metastases

2. Radiation therapy

- Rectal cancer-helps prevent local recurrence

3. Pharmaceuticals

- Stage III and IV disease

TREATMENT: Pharmaceuticals

1. 5-Fluorouracil

- pyrimidine antimetabolite

2. Irinotecan

- topoisomerase inhibitor

prevents re-ligation after cleavage of DNA by topoisomerase I

3. Oxaliplatin

- alkylating agent, causes formation of bulky DNA adducts

Exciting new biologics...

4. Bevacizumab

- Antibody against VEGF
- May block angiogenesis and also stabilize leaky vasculature

5. Cetuximab, Panitumomab

- Antibodies against EGFR
- Binds to EGF receptor on tumor cells, prevents dimerization and cell signaling


Bevacizumab toxicities

- Bleeding
- Thrombosis
- Hypertension
- Wound healing complications
- Half life about 3 weeks; wait at least 2 half-lives before major surgery

EGFR inhibition and rash



Correlating Survival With Skin Rash



* Log-rank P value, grade 0 vs. grades 1-3

Saltz L et al. *Proc Am Soc Clin Oncol* 2003; 22:204 (abstract 817)

Slide courtesy of Josep Tabernero, MD

Original Article

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer


Eric Van Cutsem, M.D., Ph.D., Claus-Henning Köhne, M.D., Erika Hitre, M.D., Ph.D., Jerzy Zaluski, M.D., Chung-Rong Chang Chien, M.D., Anatoly Makhson, M.D., Ph.D., Geert D'Haens, M.D., Ph.D., Tamás Pintér, M.D., Robert Lim, M.B., Ch.B., György Bodoky, M.D., Ph.D., Jae Kyung Roh, M.D., Ph.D., Gunnar Folprecht, M.D., Paul Ruff, M.D., Christopher Stroh, Ph.D., Sabine Tejpar, M.D., Ph.D., Michael Schlichting, Dipl.-Stat., Johannes Nippgen, M.D., and Philippe Rougier, M.D., Ph.D.

N Engl J Med
Volume 360(14):1408-1417
April 2, 2009




The NEW ENGLAND
JOURNAL of MEDICINE

Molecularly Targeted Therapy in Oncology




Slide courtesy of Wells
Messersmith, MD

Hazard Ratios for Progression-free and Overall Survival and Odds Ratios with Tumor Response, According to the Mutation Status of KRAS in the Tumor



Van Cutsem E et al. N Engl J Med 2009;360:1408-1417

Molecularly Targeted Therapy in Oncology



Slide courtesy of Wells
Messersmith, MD

TREATMENT

Pharmaceuticals

1. “Adjuvant” (after surgery)

Curative goal in patients after complete resection

2. Palliation in patients with gross metastatic disease

3. “Neoadjuvant” (before surgery)


Shrink tumors, then try to resect in limited metastatic disease

TREATMENT:


Metastatic disease

- Systemic chemotherapy now has improved survival for those with metastatic disease to about 2 years
- We now sometimes treat neoadjuvantly (before surgery), shrinking metastases and then surgically removing them
- This is important, because some of these “limited metastases” patients are cured!

Trends in the Median Survival of Patients with Advanced Colorectal Cancer



Estimated drug costs for eight weeks of treatment for metastatic colorectal cancer



Conclusions:

- Know HNPCC and APC—these may help you prevent cancers in others
- Understand how colon cancer commonly presents (right versus left-sided), and common sites of spread
- Think about colon (or other GI) cancer in an older person with iron-deficiency anemia—don't just give them iron!
- Don't give up on those with metastatic disease with new treatment options and occasionally cures

- My email:
- aas54@columbia.edu
- Many thanks to Tom Garrett for several slides!